TXNIP and sarcoma: Notably, SD3 was enriched in the negative regulation of RIG‐I signalling with high expression of BTNL9 and TXNIP, indicating endogenous anti‐immune activation and an anti‐antigen presentation module in sarcoma (Figure 5C,D).